COSENTYX Market

“Cosentyx Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about Cosentyx for lupus nephritis in the seven major markets. A detailed picture of the Cosentyx for lupus nephritis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the Cosentyx for lupus nephritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Cosentyx market forecast analysis for lupus nephritis in the 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in lupus nephritis.

Drug Summary

Cosentyx (secukinumab), which Novartis is developing – is an intravenously administered recombinant human monoclonal IgG1/κ antibody that binds specifically to interleukin-17A (IL-17A), an important cytokine involved in the inflammation lupus nephritis. Cosentyx is the first and only fully human biologic that directly inhibits IL-17A. It is a recombinant human monoclonal IgG1/κ antibody that binds specifically to IL-17A. It is expressed in a recombinant Chinese Hamster Ovary (CHO) cell line. Secukinumab has a molecular mass of approximately 151 kDa; both heavy chains of secukinumab contain oligosaccharide chains. IL-17A is the principal effector of TH17 cells and plays an important role in host defense against extracellular bacteria and fungi at mucosal surfaces. It also promotes inflammatory pathology in autoimmune diseases and activates a highly proinflammatory program of gene expression.

Currently, the drug is being evaluated in two Phase III (NCT05232864, NCT04181762) clinical trials in the United States in adults with lupus nephritis. Both the trials are being conducted to evaluate secukinumab’s efficacy, safety, and tolerability in patients with active lupus nephritis.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Cosentyx description, mechanism of action, dosage and administration, research and development activities in lupus nephritis.
• Elaborated details on Cosentyx regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Cosentyx research and development activities in lupus nephritis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Cosentyx.
• The report contains forecasted sales of Cosentyx for lupus nephritis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for lupus nephritis.
• The report also features the SWOT analysis with analyst views for Cosentyx in lupus nephritis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

• Cosentyx Analytical Perspective by DelveInsight

In-depth Cosentyx Market Assessment

This report provides a detailed market assessment of Cosentyx for lupus nephritis in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data of Cosentyx.

• Cosentyx Clinical Assessment

The report provides the clinical trials information of Cosentyx for lupus nephritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for lupus nephritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Cosentyx dominance.
• Other emerging products for lupus nephritis are expected to give tough market competition to Cosentyx and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Cosentyx in lupus nephritis.
• Our in-depth analysis of the forecasted sales data of Cosentyx will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Cosentyx in lupus nephritis.

Key Questions

• What is the product type, route of administration and mechanism of action of Cosentyx?
• What is the clinical trial status of the study related to Cosentyx in lupus nephritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Cosentyx development?
• What are the key designations that have been granted to Cosentyx for lupus nephritis?
• What is the forecasted market scenario of Cosentyx for lupus nephritis?
• What are the forecasted sales of Cosentyx in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to Cosentyx for lupus nephritis?
• Which are the late-stage emerging therapies under development for the treatment of lupus nephritis?